#Madrid #ESMO26 | Main findings from INTerpath-001 released: #Intismeran + #pembrolizumab reduced risk of recurrence or death by 42% (HR, 0.58), risk of distant metastasis or death

Ahmad Tarhini· @ATarhiniMDPhD · X·2026-10-24 04:41· 1 天前评分70

正文 · 原文

#Madrid #ESMO26 | Main findings from INTerpath-001 released: #Intismeran + #pembrolizumab reduced risk of recurrence or death by 42% (HR, 0.58), risk of distant metastasis or death by 38% (HR, 0.62); 24-monRFS rates 82.2% vs 70.0% | Proud to be part of this effort @MoffittNews

157 浏览 · 1 赞 · 0 转发 · 0 回复

会议摘要

LBA1按 Presidential Symposium I 对上

INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)

https://esmocongress.esmo.org

NCT05933577NCT05933577按 INTerpath-001 对上

INTerpath-001

https://esmocongress.esmo.org

来源：Ahmad Tarhini · x.com